Staphylococcus aureus toxoid multivalent vaccine (Integrated BioTherapeutics)
- Generic Name
- Staphylococcus aureus toxoid multivalent vaccine (Integrated BioTherapeutics)
A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.
Phase 1
Recruiting
- Conditions
- Staphylococcus (S.) Aureus Infection
- Interventions
- Biological: Placebo
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- LimmaTech Biologics AG
- Target Recruit Count
- 129
- Registration Number
- NCT06719219
- Locations
- 🇺🇸
Naval Medical Research Command Clinical Trial Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath